<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122609">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01782872</url>
  </required_header>
  <id_info>
    <org_study_id>2012-014</org_study_id>
    <nct_id>NCT01782872</nct_id>
  </id_info>
  <brief_title>Analgesia After Total Shoulder Arthroplasty</brief_title>
  <official_title>Analgesia After Total Shoulder Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which medication(s) should be included in the
      interscalene nerve block (an injection of local anesthetic [numbing medicine] near nerves in
      the shoulder) for patients undergoing total shoulder arthroplasty (shoulder replacement).
      The ideal nerve block would reduce pain after shoulder surgery without causing a great deal
      of muscle weakness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive an intravenous pain pump (patient-controlled analgesia) and a
      nerve block with long-lasting local anesthetic. The three study groups will receive
      additives (clonidine, dexamethasone, buprenorphine plus local anesthetic) in the nerve block
      that may reduce postoperative pain. One of the study groups uses the usual concentration of
      local anesthetic, while the other two study groups use reduced concentrations of local
      anesthetic. Follow-up with study patients begins on the day of surgery and continues through
      postoperative day 2. Seen twice daily, patients will be asked about their pain and assessed
      for sensory function and strength of their shoulder muscle and hand grip.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Numeric Rating Scale (NRS) Pain Score with Movement</measure>
    <time_frame>24 hours after the interscalene block is given</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain with movement at 24 hours from the nerve block (scale of 0-10; 0 = no pain, 10 = worst possible pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Analgesia from Interscalene Nerve Block</measure>
    <time_frame>Postoperative day 1 at 8AM &amp; 5PM, postoperative day 2 at 8AM &amp; 5PM</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be asked about the duration of analgesia from an analgesic interscalene block at each visit until the block has resolved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric Rating Scale (NRS) Pain Scores at Rest and with Movement</measure>
    <time_frame>Day of surgery (preop &amp; 1-2 hours after arrival in the Post Anesthesia Care Unit), postoperative day 1 at 8AM &amp; 5PM, postoperative day 2 at 8AM &amp; 5PM</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of NRS pain scores (scale of 0-10; 0 = no pain, 10 = worst possible pain) at rest and with movement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Middle Deltoid &amp; Hand Grip Strength</measure>
    <time_frame>Day of surgery (preop &amp; 1-2 hours after arrival in the Post Anesthesia Care Unit), postoperative day 1 at 8AM &amp; 5PM, postoperative day 2 at 8AM &amp; 5PM</time_frame>
    <safety_issue>No</safety_issue>
    <description>A physical assessment will be done to determine the strength of the middle deltoid muscle and hand grip in the operative arm using a dynamometer</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Total Shoulder Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Interscalene Block (ISB) - 0.375% Ropivacaine + additives</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Interscalene Block (ISB) - 0.2% Ropivacaine + additives</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Interscalene Block (ISB) - 0.1% Ropivacaine + additives</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Interscalene Block (ISB) - Systemic Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Interscalene Block (ISB) - 0.375% Ropivacaine + additives</intervention_name>
    <description>Ultrasound-guided single-injection ISB: ropivacaine 0.375% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous (IV): saline</description>
    <arm_group_label>Interscalene Block (ISB) - 0.375% Ropivacaine + additives</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Interscalene Block (ISB) - 0.2% Ropivacaine + additives</intervention_name>
    <description>Ultrasound-guided single-injection ISB: ropivacaine 0.2% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous: saline</description>
    <arm_group_label>Interscalene Block (ISB) - 0.2% Ropivacaine + additives</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Interscalene Block (ISB) - 0.1% Ropivacaine + additives</intervention_name>
    <description>Ultrasound-guided single-injection ISB: ropivacaine 0.1% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous: saline</description>
    <arm_group_label>Interscalene Block (ISB) - 0.1% Ropivacaine + additives</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Interscalene Block (ISB) - Systemic Control</intervention_name>
    <description>Ultrasound-guided single-injection ISB: ropivacaine 0.375%; Intravenous: clonidine (100 mcg) + dexamethasone (4 mg) + buprenorphine (150 mcg)</description>
    <arm_group_label>Interscalene Block (ISB) - Systemic Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with osteoarthritis

          -  Primary total shoulder arthroplasty

          -  Age 18 to 80 years old

          -  Planned use of general anesthesia

          -  Planned use of a brachial plexus nerve block for postoperative analgesia

          -  Ability to follow study protocol

        Exclusion Criteria:

          -  Patients younger than 18 years old and older than 80

          -  Allergy or intolerance to one of the study medications

          -  Patients with an American Society of Anesthesiologists (ASA) physical status of IV

          -  Patients with insulin-dependent diabetes

          -  Patients with hepatic (liver) failure

          -  Patients with chronic renal (kidney) failure

          -  Bradycardia (heart rate &lt; 50) or hypotension (systolic blood pressure &lt; 90 mmHg)

          -  Chronic opioid use (taking opioids for longer than 3 months) (or active diagnosis of
             complex regional pain syndrome [CRPS]/reflex sympathetic dystrophy [RSD])

          -  Lack of English fluency
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques T YaDeau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>September 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
